Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Priveq Investment in connection with the investment in ROL
Mandate

Vinge has advised Priveq Investment in connection with the investment in ROL

June 16, 2021 Employment and Benefits Banking and Finance Real Estate and Construction Intellectual Property IT, Telecommunications and Outsourcing M&A Environmental Law

Today ROL offers workspace solutions including software and ergonomically optimized office furniture and store concept solutions. ROL’s offering is sold globally both through ROL’s own sales organization and distributors. In 2020, ROL had a turnover of approximately SEK 1.6 billion and 890 employees in ten different countries.

The Hjelm family has partnered with Priveq Investment as a new minority owner to support the company in its accelerated growth strategy. The Hjelm family will continue as majority owners in ROL, with Arne Karlsson continuing as the Chairman of the Board.

Vinge’s team consisted of Jonas Johansson, Karl Klackenberg and Jesper Lindvall (M&A), together with Kristoffer Larson (Real Estate), Johan Cederblad and Lina Österberg (Environment), Jolene Reimerson and Mathilda Persson (IT, Agreements and GDPR), Sofia Bergenstråhle (IP), Karl-Gustaw Tobola (Financing), Ebba Svenburg (Employment), Carl Bruneheim and Viktoria Owetz Leyva (VDR).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026